London & Capital Asset Management Ltd Purchases Shares of 10,700 Arrowhead Pharmaceuticals, Inc. $ARWR

London & Capital Asset Management Ltd acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 10,700 shares of the biotechnology company’s stock, valued at approximately $369,000.

Other large investors also recently made changes to their positions in the company. Virtus Advisers LLC acquired a new stake in Arrowhead Pharmaceuticals during the 2nd quarter worth approximately $34,000. Salomon & Ludwin LLC bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter worth $34,000. Nisa Investment Advisors LLC lifted its holdings in shares of Arrowhead Pharmaceuticals by 75.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,032 shares of the biotechnology company’s stock worth $48,000 after buying an additional 1,308 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Arrowhead Pharmaceuticals in the third quarter valued at about $52,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 2,186.5% in the third quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 1,618 shares during the period. Institutional investors own 62.61% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ARWR shares. Piper Sandler reaffirmed an “overweight” rating and set a $110.00 price target (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 13th. B. Riley Financial raised their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, February 10th. Royal Bank Of Canada increased their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research report on Thursday, December 11th. Finally, Chardan Capital lifted their price objective on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $81.67.

Arrowhead Pharmaceuticals Stock Performance

Shares of NASDAQ:ARWR opened at $63.27 on Monday. Arrowhead Pharmaceuticals, Inc. has a 1 year low of $9.57 and a 1 year high of $76.76. The stock has a market capitalization of $8.86 billion, a price-to-earnings ratio of 41.35 and a beta of 1.23. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.38 and a quick ratio of 3.38. The company’s 50 day simple moving average is $66.12 and its 200 day simple moving average is $48.75.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business had revenue of $264.03 million during the quarter, compared to analyst estimates of $225.66 million. During the same period in the prior year, the business posted ($1.39) EPS. The company’s revenue for the quarter was up 10461.3% compared to the same quarter last year. As a group, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director Adeoye Y. Olukotun sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $67.66, for a total value of $676,600.00. Following the sale, the director directly owned 33,600 shares in the company, valued at approximately $2,273,376. This trade represents a 22.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 13,187 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $66.10, for a total transaction of $871,660.70. Following the sale, the chief executive officer directly owned 3,792,739 shares in the company, valued at $250,700,047.90. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 502,086 shares of company stock valued at $33,109,648 over the last ninety days. 3.60% of the stock is owned by insiders.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.